期刊文献+

帕米膦酸二钠治疗绝经后妇女骨质疏松症3年临床观察 被引量:6

The clinical observation of the postmenopausal osteoporosis women with the treatment of Pamidronate disodium in three years
暂未订购
导出
摘要 目的观察帕米膦酸二钠治疗绝经后妇女骨质疏松症(PMOP)3年疗效。方法选取2007年8月至2008年6月PMOP患者97例,每月3次静脉输注帕米膦酸钠30 mg,同时每天补充钙剂800~1 200 mg和活性维生素D 0.25μg,疗程3年。定期测定治疗前后腰椎、股骨颈与全髋骨密度值(BMD)及骨转换标记物(血清CTX、尿CTX、NTX、血清TRACP5b)。结果①治疗3年后,腰椎、股骨颈和全髋部位BMD均较治疗前相比,差异有统计学意义(P<0.001);②治疗6个月,血清I型胶原交联羧基端肽(CTX)、I型胶原交联氨基端肽(NTX)、尿CTX/Cr、尿NTX/Cr、尿吡啶啉/肌酐(PYD/Cr)、尿脱氧吡啶啉/肌酐(DPYD/Cr)和血浆抗酒石酸酸性磷酸酶均较治疗前显著下降(P<0.01),其后各骨转换标记物仍维持较低水平,但无进一步下降。Pearson相关分析显示治疗6个月时尿吡啶啉和脱氧吡啶啉、血浆抗酒石酸酸性磷酸酶的变化与3年后腰椎、股骨颈和全髋部位BMD的变化值均呈负相关(P<0.01)。③治疗后疼痛明显缓解生活能力明显改善,治疗期间新发骨折2例。结论帕米膦酸二钠治疗PMOP安全有效,早期骨转换标记物的下降与3年后骨密度的改善呈负相关。 Objective To objective the curative effect of Pamidronate disodium with the treatment of the postmenopausal osteoporosis women.Methods Selected 97 PMOP patients which were in clinic from Aug,2007 to Jun,2008.All the patients had been injected with Pamidronate disodium three times a month and taken calcium 800mg-1200mg and activated vitamin D 0.25ug everyday.The treatment lasted 3 years.Then tested the BMD of lumbar,femoral neck and total hip and tested the CTX of serum and urine,NTX and TRACP5b of serum.Results ①The treatment in the three years.(P〈0.001) The BMD of lumbar,femoral neck and total hip has been improved significantly after.②The CTX,NTX,CTX/Cr of urine,NTX/Cr of urine,PYD/Cr,DPYD/Cr and TRAP had been descended after the treatment.(P〈0.01).Then all the indexes are in a low level,no more descened.Pearson Correlation analysis shows that the changes of PYD,DPYD and PRAP at the 6th month of the treatment are in a negative correlation to the changes of BMD of lumbar,femoral neck and total hip after three years with the treatment.(P〈0.01),③All the patients had been reduced the pains and improved the ability of living.There were 2 fracture patients during the treatment.Conclusion It is safe and effective with the treatment of Pamidronate disodium to the PMOP.There is a negative correlation between the decline of BTM in the early time to the improvement of BMD after 3years.
出处 《安徽医学》 2011年第10期1698-1701,共4页 Anhui Medical Journal
关键词 帕米膦酸钠 骨密度 骨转换标记物 骨质疏松症 Pamidronate disodium BMD BTM Osteoporosis
  • 相关文献

参考文献11

  • 1Sribastava M, Deal C. Osteoporosis in early :prevention and treatment. Clin Geriatr Med,2002,18 (3) :529 - 555.
  • 2Eastell R,Hannon R. Long- term effects of aromatase inhib- itors on bone. J Steroid Biochena Mol Bio1,2005.95 (1 -5 ) : 151 - 154.
  • 3Bjarnason NH, Sarker S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenpausal osteoporosis. Osteoporos Int ,2001,12( 11 ):922 - 930.
  • 4Eastell R, Barton I,Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in, fracture risk with risedronate. J Bone Miner Res,2003,18 (6) : 1051 - 1056.
  • 5Black DM, Gummings SR, Karpf DB, et al. Randomise trial of effect of alendronate on risk of fracture women with existing vertebral fracture Intenveilion Trial Research Group. Lancet, 1996,348 (9041) : 1535 - 1541.
  • 6钟永祥,张祥斌.帕米膦酸二钠的临床应用进展[J].中华全科医师杂志,2005,4(1):27-29. 被引量:11
  • 7张秀平,俞雄.骨质疏松症防治药物研究进展[J].世界药品信息,2001,2(5):19-20. 被引量:3
  • 8Lipton A. Bisphosphonate treatment of lytic bone metasases. USA :ASCO, 1998:94 - 99.
  • 9苏秉成,董荣华,胡永成.博宁(帕米膦酸二钠)治疗骨肿瘤及骨病性疼痛的临床观察[J].中国骨肿瘤骨病,2004,3(3):147-149. 被引量:4
  • 10Lipton A,Demers L, Daniloff Y, et al. Increased urinary ex- cretion of pyfidinium cross - links in cancer patients. Clin Chan, 1993,39(4) :614 -617.

二级参考文献33

  • 1廖开莲,易立正,肖立新,殷先利,彭旭阳,袁志军,朱跃红.骨膦治疗恶性肿瘤骨转移22例临床应用总结[J].中国肿瘤临床,1997,24(2):158-159. 被引量:17
  • 2[2]Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev, 1993; 19:79 ~ 203.
  • 3[6]Lipton A. Bisphosphonate treatment of lytic bone metastases [ R ].USA: ASCO, 1998.94 - 99.
  • 4[8]Cascin S, Graziano F, Alessandroni P, et al. Different doses of pamidronate in patients with painfal osteolytic bone metastases. Support Care Cancer, 1998,6 (2): 139.
  • 5申淑景 马智勇 李醒亚.博宁引起呼吸困难2例[J].中国新药杂志,1999,8:561-561.
  • 6Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and caicium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.J Bone Miner Res. 2001.16:104-112.
  • 7Morabito N, Gaudio A, Lasco A, et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postemenopausal osteoporosis. Osteoporos Int,2003,14 :500-506.
  • 8Bartram SA, Peaston RT, Rawlings DJ, et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Phamacol Ther,2003.18 : 1121-1127.
  • 9Senaratne SG, Pirianov G, Mansi JL. Bisphosphonates induce apoptosis in human breast cancer cell lines. J Pediatr Endocrinol Metab ,2002,15 : 163-174.
  • 10Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop,1970,73:8-32.

共引文献34

同被引文献60

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部